Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis
- 1 July 2001
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 4 (4) , 316-328
- https://doi.org/10.1046/j.1524-4733.2001.44037.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Early introduction of dopamine agonists in the long-term treatment of Parkinson's diseaseNeurology, 1998
- Management of response fluctuationsNeurology, 1998
- Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patientsNeurology, 1998
- Mortality in DATATOP: A Multicenter trial in early Parkinson's diseaseAnnals of Neurology, 1998
- The Economic Impact of Parkinson???s DiseasePharmacoEconomics, 1998
- Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiologyMovement Disorders, 1994
- Epidemiology of Parkinson’s DiseaseNeurologic Clinics, 1992
- Parkinson's disease incidence: magnitude, comparability, time trendsActa Neurologica Scandinavica, 1991
- A case‐control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's diseaseNeurology, 1987
- Problems associated with long-term levodopa treatment of Parkinson's diseaseActa Neurologica Scandinavica, 1983